Mark Mercola

14.5k total citations · 1 hit paper
166 papers, 10.4k citations indexed

About

Mark Mercola is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Cellular and Molecular Neuroscience. According to data from OpenAlex, Mark Mercola has authored 166 papers receiving a total of 10.4k indexed citations (citations by other indexed papers that have themselves been cited), including 134 papers in Molecular Biology, 28 papers in Cardiology and Cardiovascular Medicine and 23 papers in Cellular and Molecular Neuroscience. Recurrent topics in Mark Mercola's work include Congenital heart defects research (47 papers), Pluripotent Stem Cells Research (37 papers) and Developmental Biology and Gene Regulation (30 papers). Mark Mercola is often cited by papers focused on Congenital heart defects research (47 papers), Pluripotent Stem Cells Research (37 papers) and Developmental Biology and Gene Regulation (30 papers). Mark Mercola collaborates with scholars based in United States, Germany and China. Mark Mercola's co-authors include Michael Levin, Valérie Schneider, Charles D. Stiles, Erik Willems, Kathryn Calame, Ann Foley, Paul Bushway, Pilar Ruiz‐Lozano, Karen Symes and C D Stiles and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Mark Mercola

164 papers receiving 10.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phenotypic drug discovery: recent successes, lessons learned and new directions

2022 165 citations Fabien Vincent, Arsenio Nueda et al. Nature Reviews Drug Discovery profile →

Peers

Countries citing papers authored by Mark Mercola

Since Specialization

Citations

This map shows the geographic impact of Mark Mercola's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Mercola with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Mercola more than expected).

Fields of papers citing papers by Mark Mercola

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Mercola. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Mercola. The network helps show where Mark Mercola may publish in the future.

Co-authorship network of co-authors of Mark Mercola

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Mercola. A scholar is included among the top collaborators of Mark Mercola based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Mercola. Mark Mercola is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Uncertainty-aware traction force microscopy 2025 ·PLoS Computational Biology ·(unknown), Yi‐Ting Yeh, Ricardo Serrano, Mark Mercola, Juan C. del Álamo	2
2	Comparing the Efficacy of Myosin Inhibition Versus Thin Filament Calcium Desensitization for Treatment of Pediatric Restrictive Cardiomyopathy Using a Patient-Derived hiPSC Model 2025 ·Circulation Genomic and Precision Medicine ·David Staudt, Ricardo Serrano, (unknown), Isaac C. Sánchez, (unknown), Dries Feyen, Mark Mercola	0
3	Phenotypic drug discovery: recent successes, lessons learned and new directions breakdown → 2022 ·Nature Reviews Drug Discovery ·Fabien Vincent, Arsenio Nueda, Jonathan Lee, Monica Schenone, Marco Prunotto, Mark Mercola	165
4	Reengineering Ponatinib to Minimize Cardiovascular Toxicity 2022 ·Cancer Research ·(unknown), Arne A.N. Bruyneel, Dhanir Tailor, Mallesh Pandrala, (unknown), Wenqi Li, Ricardo Serrano, Dries Feyen, Michelle M. Vu, Prashila Amatya, (unknown), Yusuke Nakauchi, Isabel Morgado, Volker Wiebking, Ronglih Liao, Matthew H. Porteus, Ravindra Majeti, Sanjay V. Malhotra, Mark Mercola	14
5	Publisher Correction: Phenotypic drug discovery: recent successes, lessons learned and new directions 2022 ·Nature Reviews Drug Discovery ·Fabien Vincent, Arsenio Nueda, (unknown), Monica Schenone, Marco Prunotto, Mark Mercola	6
6	miR-106a–363 cluster in extracellular vesicles promotes endogenous myocardial repair via Notch3 pathway in ischemic heart injury 2021 ·Basic Research in Cardiology ·Ji‐Hye Jung, Gentaro Ikeda, Yuko Tada, Daniel von Bornstädt, Michelle Santoso, Christine Wahlquist, Siyeon Rhee, Young-Jun Jeon, Anthony C. Yu, Connor O’Brien, Kristy Red‐Horse, Eric A. Appel, Mark Mercola, Young Woo, Phillip C. Yang	40
7	Mapping genetic variability in mature miRNAs and miRNA binding sites in prostate cancer 2021 ·Journal of Human Genetics ·Bongyong Lee, Jian‐Liang Li, (unknown), Mark Mercola, Vipul Patel, Ranjan J. Perera	4
8	iPSC Modeling of RBM20-Deficient DCM Identifies Upregulation of RBM20 as a Therapeutic Strategy 2020 ·Cell Reports ·Francesca Briganti, Han Sun, Wei Wu, Jingyan Wu, Chenchen Zhu, Martin Liss, Ioannis Karakikes, Shannon Rego, Andrea Cipriano, M Snyder, Benjamin Meder, Zhenyu Xu, Gilles Millat, Michael Gotthardt, Mark Mercola, Lars M. Steinmetz	40
9	A Novel Recessive Mutation in SPEG Causes Early Onset Dilated Cardiomyopathy 2020 ·PLoS Genetics ·Aviva Levitas, Emad Muhammad, Yuan Zhang, Isaac Perea‐Gil, Ricardo Serrano, (unknown), (unknown), (unknown), Michael S. Kapiloff, Mark Mercola, Yoram Etzion, Ruti Parvari, Ioannis Karakikes	21
10	A Novel Inhibitor Targets Both Wnt Signaling and ATM/p53 in Colorectal Cancer 2018 ·Cancer Research ·Jiongjia Cheng, Mary A. Dwyer, Karl J. Okolotowicz, Mark Mercola, John R. Cashman	22
11	High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells 2017 ·Science Translational Medicine ·Arun Sharma, Paul W. Burridge, Wesley L. McKeithan, Ricardo Serrano, Praveen Shukla, Nazish Sayed, Jared M. Churko, Tomoya Kitani, Haodi Wu, Alexandra Holmström, Elena Matsa, Yuan Zhang, Anusha Kumar, Alice C. Fan, Juan C. del Álamo, Sean M. Wu, Javid J. Moslehi, Mark Mercola, Joseph C. Wu	287
12	miR-322/-503 cluster is expressed in the earliest cardiac progenitor cells and drives cardiomyocyte specification 2016 ·Proceedings of the National Academy of Sciences ·(unknown), Benjamin Soibam, Ashley Benham, Xueping Xu, Mani Chopra, Xiaoping Peng, Wei Yu, Wenjing Bao, Rui Liang, Alon R. Azares, Peijun Liu, Preethi H. Gunaratne, Mark Mercola, Austin J. Cooney, Robert J. Schwartz, Yu Liu	63
13	High Content Screening for Modulators of Cardiac Differentiation in Human Pluripotent Stem Cells 2014 ·Methods in molecular biology ·Sean Spiering, (unknown), Paul Bushway, Mark Mercola, Erik Willems	3
14	Inhibition of miR-25 improves cardiac contractility in the failing heart 2014 ·Nature ·Christine Wahlquist, Dongtak Jeong, Agustin Rojas‐Muñoz, Changwon Kho, Ah Young Lee, Shinichi Mitsuyama, Alain van Mil, Woo Jin Park, Joost P. G. Sluijter, Pieter A. Doevendans, Roger J. Hajjar, Mark Mercola	326
15	Alternative splicing regulates mouse embryonic stem cell pluripotency and differentiation 2010 ·Proceedings of the National Academy of Sciences ·Nathan Salomonis, Christopher R. Schlieve, Laura Pereira, Christine Wahlquist, Alexandre R. Colas, Alexander C. Zambon, Karen Vranizan, Matthew Spindler, Alexander R. Pico, Melissa Cline, Tyson A. Clark, Alan J. Williams, John E. Blume, Eva Samal, Mark Mercola, Bradley J. Merrill, Bruce R. Conklin	175
16	Hybrid Median Filter Background Estimator for Correcting Distortions in Microtiter Plate Data 2010 ·Assay and Drug Development Technologies ·Paul Bushway, (unknown), Susanne Heynen‐Genel, Jeffrey H. Price, Mark Mercola	5
17	Non-Cardiomyocytes Influence the Electrophysiological Maturation of Human Embryonic Stem Cell-Derived Cardiomyocytes During Differentiation 2009 ·Stem Cells and Development ·(unknown), (unknown), Peng Xia, (unknown), Maria Talantova, Sean Spiering, Brandon Nelson, Mark Mercola, Huei-Sheng Vincent Chen	138
18	A Comparative Analysis of Standard Microtiter Plate Reading Versus Imaging in Cellular Assays 2008 ·Assay and Drug Development Technologies ·Paul Bushway, Mark Mercola, Jeffrey H. Price	18
19	Zebrafish narrowminded disrupts the transcription factor prdm1 and is required for neural crest and sensory neuron specification 2004 ·Developmental Biology ·Laura Hernandez‐Lagunas, (unknown), Takao Kaji, Peter Simpson, (unknown), Yi Zhou, L I Zon, Mark Mercola, Kristin Artinger	91
20	PDGF mediates cardiac microvascular communication. 1998 ·Journal of Clinical Investigation ·Jay M. Edelberg, William C. Aird, Wei Wu, Helen Rayburn, Wilfred Mamuya, Mark Mercola, Robert Rosenberg	88

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact